{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/warts-anogenital/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"3ca6914f-3aca-5823-b591-4de01ae58b9d","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 5430ffac-243a-4154-b2dc-e9739cff0a9e --><h2>Changes</h2><!-- end field 5430ffac-243a-4154-b2dc-e9739cff0a9e -->","summary":null,"htmlStringContent":"<!-- begin item 38f21c80-0071-420f-b731-1bdbeb2c3046 --><!-- begin field 45be4484-c647-40c9-97d4-b30721495ea4 --><p><strong>April to May 2017</strong> — reviewed. A literature search was conducted in April 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. Some minor structural changes have been made to this topic, and information that sinecatechins ointment 10% is now a treatment option has been added.</p><!-- end field 45be4484-c647-40c9-97d4-b30721495ea4 --><!-- end item 38f21c80-0071-420f-b731-1bdbeb2c3046 -->","topic":{"id":"e7a3f2d8-5f5c-5ba5-a771-18dfa2a34ece","topicId":"2ff76478-9567-414a-a850-4f9608dd4feb","topicName":"Warts - anogenital","slug":"warts-anogenital","lastRevised":"Last revised in April 2017","chapters":[{"id":"673e021d-a2fb-52b7-bcd9-3467b771a57f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ac99c8bf-87d2-52a1-8485-e38fee62d2d3","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7ee801e8-cb99-5752-81b8-62e0d1660af0","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3ca6914f-3aca-5823-b591-4de01ae58b9d","slug":"changes","fullItemName":"Changes"},{"id":"ca4c177d-14a1-5222-bb51-8c52162b0687","slug":"update","fullItemName":"Update"}]},{"id":"7970a29f-32ff-5788-992e-9a2a02fd909e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"78ac4b28-280b-5af0-9547-55357fce168f","slug":"goals","fullItemName":"Goals"},{"id":"9b223dc3-5b17-5d5e-a693-4e5c5d7f89a4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8c1c2a62-d986-55e6-9131-7eeb96cd8c26","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d5e6469f-75c7-5a1c-8dea-d31a4c066353","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d2692bb1-78d5-5ce8-a2c2-252f1f8238ca","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"43a07fd6-910a-5025-a989-3db317b8cd1c","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"98c96f9a-dadf-585b-af6c-70cfbaa769af","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7a459ab9-55fe-5d56-9c06-35b3447cf0f3","slug":"definition","fullItemName":"Definition"},{"id":"9501b6fc-6ddf-57da-b4a1-0de76a0c7c49","slug":"causes","fullItemName":"Causes"},{"id":"c22bc57c-cdd6-5330-b88f-11aa440a0bd3","slug":"transmission","fullItemName":"Transmission"},{"id":"63eca59f-4ff0-5ce0-a4cb-e893f95d6d40","slug":"prevalence","fullItemName":"Prevalence"},{"id":"67bcb534-24c1-5405-a371-00e3b3234238","slug":"complications","fullItemName":"Complications"},{"id":"9f628e4f-fe37-5c7b-b9b9-68ca563cc306","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"750b2924-a2af-5b82-9d04-8071a886ec8f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"45d6382a-5bf8-52dc-be32-eca7478a9a0d","slug":"assessment","fullItemName":"Assessment"},{"id":"126f2080-3e60-5a09-a26a-8a13d5e050ea","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"a3122ed7-4faf-52d8-8714-99ebcc69d085","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"12587369-d043-546c-adf4-e1e5572741f1","fullItemName":"Management","slug":"management","subChapters":[{"id":"c91156c1-59d1-5b14-8f39-bf08dc3bc8f9","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"f5a42760-c0e3-56e3-b935-d180d409a30e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ed0173f4-aefc-569f-81f2-19df322c9290","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"913d974d-9c96-5914-836f-e8e7f72f78b3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"35560bdc-50e2-5351-9d97-40d6da9f9c18","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"813cc37b-94d6-545a-844e-7d6f84d0e99c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fc968029-b704-5091-ba16-92aeefda51c2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"81cb227a-e86d-54e1-942c-456ae8251dc2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c81502ec-60d8-5a69-ad22-46e42e704b95","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7ee801e8-cb99-5752-81b8-62e0d1660af0","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"da02d3ce-ffad-5541-aca7-3925d41d7eaa","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field e9e90850-4f46-4da1-b714-cb4636353e5b --><h3>Previous changes</h3><!-- end field e9e90850-4f46-4da1-b714-cb4636353e5b -->","summary":null,"htmlStringContent":"<!-- begin item fe552513-5590-41c5-802c-982e3f4824ec --><!-- begin field e9154f8d-3e47-4653-af24-c14278f85691 --><p><strong>May 2014 </strong>— minor update. The link to prescriptions has been removed.</p><p><strong>November 2012 </strong>— minor update. The links to the electronic medicines website (<a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"d346d3e6-1e1f-4fb6-898c-a992016de80e\">www.medicines.org.uk</a>) have been updated.</p><p><strong>November 2012</strong> — reviewed. A literature search was conducted in September 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. No changes to clinical recommendations have been made.</p><p><strong>January 2012 </strong>— minor update. Typographical errors corrected. Issued in February 2012.</p><p><strong>September 2010 </strong>— minor update. The figures for new diagnoses of anogenital warts in 2008/9 have been added, and secondary syphilis has been added as a possible differential diagnosis. Issued in September 2010.</p><p><strong>December 2008 </strong>— minor update. Warticon FEM<sup>® </sup>has been discontinued; the manufacturer has advised that Warticon<sup>®</sup>should be used for both men and women. Prescriptions for Warticon FEM<sup>® </sup>have been deleted. Issued in January 2009.</p><p><strong>November 2008 </strong>— minor update. Black triangle removed from imiquimod. Issued in December 2008.</p><p><strong>July to October 2008 </strong>— this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field e9154f8d-3e47-4653-af24-c14278f85691 --><!-- end item fe552513-5590-41c5-802c-982e3f4824ec -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}